The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Open accessAbstract
BACKGROUND: Phase 2 studies suggest that the standard regimen of cisplatin and fluorouracil (PF) plus docetaxel (TPF) improves outcomes in squamous-cell carcinoma of the head and neck. We compared TPF with PF as induction chemotherapy in patients with locoregionally advanced, unresectable disease. METHODS: We randomly assigned eligible patients between the ages of 18 and 70 years who had stage III or stage IV disease and no distant metastases to receive either TPF (docetaxel and cisplatin, day 1; fluorouracil by continuous infusion, days 1 to 5) or PF every 3 weeks for four cycles. Patients without progression of disease received radiotherapy within 4 to 7 weeks after completing chemotherapy. The primary end point was progression-free survival. RESULTS: A total of 358 patients underwent randomization, with 177 assigned to the TPF group and 181 to the PF group. At a median follow-up of 32.5 months, the median progression-free survival was 11.0 months in the TPF group and 8.2 months in the PF group (hazard ratio for disease progression or death in the TPF group, 0.72; P=0.007). Treatment with TPF resulted in a reduction in the risk of death of 27% (P=0.02), with a median overall survival of 18.8 months, as compared with 14.5 months in the PF group. There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group. The rates of death from toxic effects were 2.3% in the TPF group and 5.5% in the PF group. CONCLUSIONS: As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00003888 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070956 · Cited by 1,705
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Bourhis, J., Overgaard, J., Audry, H., Ang, K. K., Saunders, M., Bernier, J., Horiot, J.-C., Le Maître, A., Pajak, T. F., Poulsen, M. G., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69121-6 · Cited by 1,085
Self-citationHitt, R., López-Pousa, A., Martínez-Trufero, J., Escrig, V., Carles, J., Rizo, A., Isla, D., Vega, M. E., Martí, J. L., Lobo, F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1990 · Cited by 455
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma
Domenge, C., Hill, C., Lefebvre, J. L., De Raucourt, D., Rhein, B., Wibault, P., Marandas, P., Coche-Dequeant, B., Stromboni-Luboinski, M., Sancho-Garnier, H., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1512 · Cited by 254
Self-citationOverview of Combined Modality Therapies for Head and Neck Cancer
Dimery, I. W., & Hong, W. K. (1993) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/85.2.95 · Cited by 210
Cited by
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070956 · Cited by 1,705
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.12.017 · Cited by 1,174
Sun, Y., Li, W.-F., Chen, N.-Y., Zhang, N., Hu, G.-Q., Xie, F.-Y., Sun, Y., Chen, X.-Z., Li, J.-G., Zhu, X.-D., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30410-7 · Cited by 950
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Zhang, Y., Chen, L., Hu, G.-Q., Zhang, N., Zhu, X.-D., Yang, K.-Y., Jin, F., Shi, M., Chen, Y.-P., Hu, W.-H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905287 · Cited by 927
Recent Advances in Head and Neck Cancer
Haddad, R. I., & Shin, D. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707975 · Cited by 916
Machiels, J.-P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., & Gregoire, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.011 · Cited by 916
Mody, M. D., Rocco, J. W., Yom, S. S., Haddad, R. I., & Saba, N. F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01550-6 · Cited by 847
The changing therapeutic landscape of head and neck cancer
Cramer, J. D., Burtness, B., Le, Q. T., & Ferris, R. L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0227-z · Cited by 783
Haddad, R., O'Neill, A., Rabinowits, G., Tishler, R., Khuri, F., Adkins, D., Clark, J., Sarlis, N., Lorch, J., Beitler, J. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70011-1 · Cited by 750
Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment
Marur, S., & Forastiere, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.489 · Cited by 739
Steuer, C. E., El‐Deiry, M., Parks, J. R., Higgins, K. A., & Saba, N. F. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21386 · Cited by 672
Grégoire, V., Lefebvre, J.-L., Licitra, L., & Felip, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq185 · Cited by 628
Self-citationBlanchard, P., Baujat, B., Holostenco, V., Bourredjem, A., Baey, C., Bourhis, J., & Pignon, J.-P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.036 · Cited by 621
Pointreau, Y., Garaud, P., Chapet, S., Sire, C., Tuchais, C., Tortochaux, J., Faivre, S., Guerrif, S., Alfonsi, M., & Calais, G. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp007 · Cited by 577
Cohen, E. E. W., Karrison, T. G., Kocherginsky, M., Mueller, J., Egan, R., Huang, C. H., Brockstein, B. E., Agulnik, M. B., Mittal, B. B., Yunus, F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.6309 · Cited by 571
Hui, E. P., Ma, B. B., Leung, S. F., King, A. D., Mo, F., Kam, M. K., Yu, B. K., Chiu, S. K., Kwan, W. H., Ho, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1545 · Cited by 523
Lorch, J. H., Goloubeva, O., Haddad, R. I., Cullen, K., Sarlis, N., Tishler, R., Tan, M., Fasciano, J., Sammartino, D. E., & Posner, M. R. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70279-5 · Cited by 448
Predictors of Competing Mortality in Advanced Head and Neck Cancer
Mell, L. K., Dignam, J. J., Salama, J. K., Cohen, E. E. W., Polite, B. N., Dandekar, V., Bhate, A. D., Witt, M. E., Haraf, D. J., Mittal, B. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9288 · Cited by 433
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0053 · Cited by 413
Zhong, L.-P., Zhang, C.-P., Ren, G.-X., Guo, W., William, W. N., Sun, J., Zhu, H.-G., Tu, W.-Y., Li, J., Cai, Y.-L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.8820 · Cited by 394
Cardiovascular Complications of Cancer Therapy
Chang, H.-M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1096 · Cited by 385
Optimal treatment for recurrent/metastatic head and neck cancer
Vermorken, J. B., & Specenier, P. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq453 · Cited by 383
Self-citationElting, L. S., Keefe, D. M., Sonis, S. T., Garden, A. S., Spijkervet, F. K. L., Barasch, A., Tishler, R. B., Canty, T. P., Kudrimoti, M. K., Vera‐Llonch, M., et al. (2008) · Cancer · doi:10.1002/cncr.23898 · Cited by 373
Forastiere, A. A., Ismaila, N., Lewin, J. S., Nathan, C. A., Adelstein, D. J., Eisbruch, A., Fass, G., Fisher, S. G., Laurie, S. A., Le, Q.-T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7385 · Cited by 364
Hitt, R., Grau, J. J., López-Pousa, A., Berrocal, A., García-Girón, C., Irigoyen, A., Sastre, J., Martínez-Trufero, J., Brandariz Castelo, J. A., Verger, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt461 · Cited by 353
Current trends in initial management of laryngeal cancer: the declining use of open surgery
Silver, C. E., Beitler, J. J., Shaha, A. R., Rinaldo, A., & Ferlito, A. (2009) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-009-1028-2 · Cited by 345
Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery
Takes, R. P., Strojan, P., Silver, C. E., Bradley, P. J., Haigentz, M., Wolf, G. T., Shaha, A. R., Hartl, D. M., Olofsson, J., Langendijk, J. A., et al. (2012) · Head & Neck · doi:10.1002/hed.21613 · Cited by 312
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Blanchard, P., Bourhis, J., Lacas, B., Posner, M. R., Vermorken, J. B., Hernandez, J. J. C., Bourredjem, A., Calais, G., Paccagnella, A., Hitt, R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7802 · Cited by 300
Self-citationLefebvre, J. L., Rolland, F., Tesselaar, M., Bardet, E., Leemans, C. R., Geoffrois, L., Hupperets, P., Barzan, L., de Raucourt, D., Chevalier, D., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn460 · Cited by 285
Self-citationHead and Neck Cancers, Version 2.2014
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0142 · Cited by 283
Kato, K., Machida, R., Ito, Y., Daiko, H., Ozawa, S., Ogata, T., Hara, H., Kojima, T., Abe, T., Bamba, T., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00745-1 · Cited by 280
Ang, K. K., & Sturgis, E. M. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.12.004 · Cited by 260
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Head and neck cancer: An evolving treatment paradigm
Cognetti, D. M., Weber, R. S., & Lai, S. Y. (2008) · Cancer · doi:10.1002/cncr.23654 · Cited by 253
Kies, M. S., Holsinger, F. C., Lee, J. J., William, W. N., Glisson, B. S., Lin, H. Y., Lewin, J. S., Ginsberg, L. E., Gillaspy, K. A., Massarelli, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0425 · Cited by 253
Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658636 · Cited by 193
Lechien, J. R., Briganti, G., & Vaira, L. A. (2024) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-08441-8 · Cited by 54
Jelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., & Vokes, E. E. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105171 · Cited by 20
“The response rates seen in this trial are numerically less compared to previous induction chemotherapy trials.[8, 9, 34] Patients enrolled on TAX324 received induction chemotherapy followed by definitive concurrent chemoradiation – a paradigm similar to this trial.”
BackgroundResultInfluentialTomkiewicz, C., Hans, S., Mucchielli, M. H., Agier, N., Delacroix, H., Marisa, L., Brasnu, D., Aggerbeck, L. P., Badoual, C., Barouki, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047170 · Cited by 10
Metadata
- Authors
- Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., van den Weyngaert, D., Awada, A., Cupissol, D., Kienzer, H. R., Rey, A., Desaunois, I., Bernier, J., & Lefebvre, J.-L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-25
- Volume
- 357
- Issue
- 17
- Pages
- 1695-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1983970003
- Cited by
- 1,719
- References
- 15
- FWCI
- 82.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.